Literature DB >> 27824847

Railroading at the FDA.

.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27824847     DOI： 10.1038/nbt.3733

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Eteplirsen for the treatment of Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422
  1 in total
  4 in total

1.  Fresh from the biotech pipeline-2016.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2017-01-30       Impact factor: 54.908

2.  Duchenne drug clings on for FDA nod.

Authors: 
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

Review 3.  The golden retriever model of Duchenne muscular dystrophy.

Authors:  Joe N Kornegay
Journal:  Skelet Muscle       Date:  2017-05-19       Impact factor: 4.912

4.  Conditional Approval Pathways: The "Special" Case of Global Regenerative Medicine Regulation.

Authors:  James A Smith; David A Brindley
Journal:  Rejuvenation Res       Date:  2017-02       Impact factor: 4.663
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.